Newsbenzinga
Summit Therapeutics Announces Closing Of AstraZeneca's $2B Convertible Preferred Investment, Equivalent To $18.36/Share Of Common Stock
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…